EventsEventsPodcasts
Loader
Find Us
ADVERTISEMENT

Pfizer in talks to merge off-patent drugs business with Mylan

Pfizer in talks to merge off-patent drugs business with Mylan
FILE PHOTO: The logo of U.S. pharmaceutical corporation Pfizer Inc. is seen at a branch in Zurich, Switzerland October 2, 2018. REUTERS/Arnd Wiegmann Copyright Arnd Wiegmann(Reuters)
Copyright Arnd Wiegmann(Reuters)
By Reuters
Published on Updated
Share this articleComments
Share this articleClose Button

(Reuters) - Pfizer Inc <PFE.N> is in talks to merge its off-patent drugs business with Mylan NV <MYL.O> in a stock deal, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

Mylan shareholders would receive a little more than 40% of the newly formed entity, with Pfizer shareholders receiving the remainder, the Journal said, adding Pfizer would also get about $12 billion in proceeds from a new sale of debt.

Pfizer and Mylan did not immediately respond to requests for comment.

(Reporting by Maria Ponnezhath in Bengaluru; Editing by Mark Potter)

Share this articleComments

You might also like